Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

The Granulomatosis of Wegener’s

Wolfgang L. Gross, MD, PhD, Antje Mueller, PhD, and Julia Holle, MD  |  Issue: May 2011  |  May 16, 2011

The Granulomatosis of Wegener's

Editor’s Note: The nomenclature for Wegener’s recently changed from Wegener’s granulomatosis to granulomatosis with polyangiitis (Wegener’s). Beginning with the June 2011 publication of The Rheumatologist, the new nomenclature will be used. See “Medical Societies Ask, What’s in a Name?“ on p. 48 for more on the evolution of disease nomenclature.

Wegener’s granulomatosis (WG) is per definitionem a granulomatous disorder involving the respiratory tract and is usually associated with vasculitis, affecting small to medium-sized vessels and the production of antibodies to neutrophil cytoplasmic antigens (ANCA) directed to the antigen proteinase 3 (PR3).1 Although vasculitis may be its classical feature, WG also may occur as a persistent granulomatous inflammatory process without apparent vasculitis.2 While there is no clear definition of granulomatous disease in WG, this pathological process relates to the formation of masses (often round in appearance on radiograph) or the histological picture of granuloma that is frequently detected within these masses. We know about the vasculitic side of WG’s coin; much less is known about the granulomatous side of WG, however. In this article, we will focus on recent clinical and immunopathological findings attributed to the so-far enigmatic granulomatous process and the probable link to the development of PR3-ANCA and vasculitis.3

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Categorizing Disease Stages

WG is commonly considered to be part of the spectrum of disorders characterized by vasculitic lesions throughout the body without a known cause but associated with autoantibodies against PR3-ANCA.4 Therefore, WG is included into the group of diseases known as primary systemic vasculitides and grouped together with others (e.g., microscopic polyangiitis, Churg-Strauss syndrome) also strongly associated with ANCA and “pauci-immune” glomerulonephritis in situ.2 There is strong evidence for the pathogenic role of antibodies against myeloperoxidase (MPO-ANCA) in inducing vasculitis, and this mechanism may also play a role in PR3-ANCA associated vasculitis such as WG.5 However, the clinical and pathological hallmark of WG is not only vasculitis but the coexistence of vasculitis and granuloma, both of which differentiate WG from microscopic polyangiitis. The presence of two distinct pathological processes needs to be considered in categorizing disease stages in WG.

Figure 1: Destructive lesions in WG.
Credit: Left and middle panels, New Engl J Med. 2005;352:392;
right panel, Arthritis Rheum. 2008;58:834.
Reprinted with permission.
Figure 1: Destructive lesions in WG. Left panel: Necrotizing inflammation of the right lower eyelid and collapse of the nasal bridge. Middle panel: Computed tomographic scan displaying a retro-orbital mass and destruction of the orbital wall. Right Panel: Histopathology revealed granulomatous and ulcerative inflammation with active destruction of nasal septal cartilage.36,37

Currently, there are two approaches to categorize disease stages in ANCA-associated vasculitis (AAV). In the United States, it is common to differentiate a limited form of WG in which patients suffer from non–life-threatening vasculitis manifestations from a severe form with life-threatening vasculitic manifestations, such as glomerulonephritis.6 In contrast, the European approach separates a disease stage with granulomatous manifestations of the upper and lower respiratory tract (and with no clinical signs of vasculitis) from systemic disease stages with granulomatous and vasculitic manifestations (early systemic, non–life-threatening; generalized, organ-threatening; and severe with organ failure).7,8

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Page: 1 2 3 4 5 6 7 | Single Page
Share: 

Filed under:ConditionsVasculitis Tagged with:Diagnostic Criteriagranulomatosis with polyangiitisPathogenesisTreatmentWegener's Granulomatosis

Related Articles

    Reading Rheum

    April 1, 2008

    Handpicked Reviews of Contemporary Literature

    Figure 2: Renal Biopsy

    The Classification & Diagnosis of Granulomatosis with Polyangiitis

    August 16, 2018

    Based on the classification system developed by the Chapel Hill Consensus Conference, anti-neutrophil cytoplasmic antibody (ANCA) associated vasculitis is defined as a necrotizing vasculitis involving small vessels that is associated with myeloperoxidase (MPO) ANCA or proteinase 3 (PR3) ANCA and displays minimal immune deposits. The mechanism behind the pathogenesis of ANCA-associated vasculitis is not fully…

    ACR Winter Rheumatology Symposium: Tips for ANCA Testing

    May 1, 2013

    How to select the correct testing method and interpret conflicting results from antineutrophil cytoplasmic antibody tests

    Wegener’s Granulomatosis Treatment Today

    October 1, 2008

    WG has an evolving prognosis and treatment course

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences